{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants will receive CYP-006TK dressings",
            "Participants will continue to be treated as per local standard of care"
      ],
      "ArmGroupInterventionName": [
            "Combination Product: CYP-006TK"
      ],
      "ArmGroupLabel": [
            "Group 1 - CYP-006TK",
            "Group 2 - Standard of Care"
      ],
      "ArmGroupType": [
            "Experimental",
            "No Intervention"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT05165628"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Design: A randomised, controlled, prospective trial. Participants will be patients with non-healing diabetic foot ulcers.\n\nThe study will aim to recruit 15 participants per study group (30 participants in total). Participants will be randomly allocated to one of two treatment groups:\n\nGroup 1: CYP-006TK\nGroup 2: Standard care This will be an open label study with respect to treatment allocation. However, the person reviewing images of the study ulcers to assess healing will be blind to the participant's treatment allocation.\n\nParticipants assigned to Group 1 will be treated with CYP-0006TK dressings on 8 occasions over 4 weeks. The dressings will be changed every 3 or 4 days. After the first 4 weeks, participants in Group 1 will revert to standard care for the rest of the study. Participants assigned to Group 2 will have their ulcer treated with standard care throughout the study.\n\nParticipants will attend a total of 16 scheduled visits over 24 weeks. There will be a mixture of on-site (hospital/clinic) visits, and home visits. The study will end 24 weeks after the initiation of treatment, unless the study ulcer is completely headed before then."
      ],
      "BriefTitle": [
            "Safety, Tolerability and Efficacy of CYP-006TK in Adults With Diabetic Foot Ulcers"
      ],
      "CentralContactEMail": [
            "clinical@cynata.com"
      ],
      "CentralContactName": [
            "Project Manager"
      ],
      "CentralContactPhone": [
            "+61 3 7067 6940"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Diabetic Foot Ulcer",
            "Cutaneous Ulcer"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000003925",
            "D000014652",
            "D000002318",
            "D000007871",
            "D000012871",
            "D000048909",
            "D000003920",
            "D000004700",
            "D000003929",
            "D000005534"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Diabetic Angiopathies",
            "Vascular Diseases",
            "Cardiovascular Diseases",
            "Leg Ulcer",
            "Skin Diseases",
            "Diabetes Complications",
            "Diabetes Mellitus",
            "Endocrine System Diseases",
            "Diabetic Neuropathies",
            "Foot Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC14",
            "BC17",
            "BC19",
            "All",
            "BC23",
            "BC18",
            "BC10",
            "BC05"
      ],
      "ConditionBrowseBranchName": [
            "Heart and Blood Diseases",
            "Skin and Connective Tissue Diseases",
            "Gland and Hormone Related Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Nutritional and Metabolic Diseases",
            "Nervous System Diseases",
            "Musculoskeletal Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Diabetic Foot",
            "Foot Ulcers",
            "Ulcer",
            "Cutaneous Ulcers"
      ],
      "ConditionBrowseLeafId": [
            "M19085",
            "M18071",
            "M16358",
            "M14838",
            "M6272",
            "M16552",
            "M10035",
            "M14826",
            "M6267",
            "M25157",
            "M7014",
            "M6276",
            "M7810"
      ],
      "ConditionBrowseLeafName": [
            "Diabetic Foot",
            "Foot Ulcer",
            "Ulcer",
            "Skin Ulcer",
            "Diabetic Angiopathies",
            "Vascular Diseases",
            "Leg Ulcer",
            "Skin Diseases",
            "Diabetes Mellitus",
            "Diabetes Complications",
            "Endocrine System Diseases",
            "Diabetic Neuropathies",
            "Foot Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000017719",
            "D000016523",
            "D000012883",
            "D000014456"
      ],
      "ConditionMeshTerm": [
            "Diabetic Foot",
            "Foot Ulcer",
            "Skin Ulcer",
            "Ulcer"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Single"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Outcomes Assessor"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nAdults at least 18 years of age up to 80 years of age, inclusive.\nHave a current diagnosis of diabetes mellitus (DM)\nWith at least one non-healing cutaneous ulcer on the foot or the lower legs\nWith ankle brachial index (ABI) \u2265 0.4 and/or toe pressure >30 mmHg on the limb with the study ulcer.\nParticipant co-morbidities are adequately managed, and the participant has a life expectancy of at least 6 months as determined by the Investigator based on medical history, physical examination, vital signs, or clinical laboratory tests, etc.\nA negative pregnancy test, (i.e. for female participants with childbearing potential).\nWilling to comply with birth control measures, to prevent female participants becoming pregnant for six months following administration of the study treatment.\nAble to follow the Investigator's instruction on ulcer care (in the opinion of the Investigator).\nAgrees to provide written informed consent.\n\nExclusion Criteria:\n\nPlanned vascular surgery, angioplasty, thrombolysis or amputation of the affected limb in the next six months.\nPregnant or breastfeeding.\nActive infection in the study ulcer.\nAny sign of osteomyelitis associated with the study ulcer.\nStudy ulcer extends to bone or periosteum (ulcers that reach a ligament, joint capsule, fascia, or tendon are not excluded).\nKnown autoimmune disease other than diabetes, including but not limited to lupus erythematosus, multiple sclerosis.\nTreatment with systemic immunosuppressants within 90 days of screening.\nActive malignancy or history of malignancy within five years prior to screening (with the exception of a past history of basal or squamous cell carcinomas).\nSerum GGT, AST or ALT > 5 \u00d7 upper limit of the normal range (ULN).\n. Known history of HIV infection\nPrior administration of any cell-based treatment to the limb affected by the study ulcer.\nReceived any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned initiation of study treatment.\nAny other medical condition or laboratory abnormality judged as clinically significant by the Investigator or study Medical Monitor which could confound the evaluation of the trial treatment.\nWith history of sensitivity to materials of bovine, porcine origin, or human serum albumin."
      ],
      "EnrollmentCount": [
            "30"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Group 1 - CYP-006TK"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus\u2122 MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "CYP-006TK"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Combination Product"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [
            "No"
      ],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "March 22, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "March 7, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Cynata Therapeutics Limited"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Adelaide"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [
            "Robert Fitridge"
      ],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact"
      ],
      "LocationCountry": [
            "Australia"
      ],
      "LocationFacility": [
            "Central Adelaide Local Health Network"
      ],
      "LocationState": [
            "South Australia"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "5000"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Randomised, Controlled, Phase 1 Study to Investigate Safety, Tolerability and Efficacy of CYP-006TK in Adults With Diabetic Foot Ulcers"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Cynata Therapeutics Limited"
      ],
      "OrgStudyId": [
            "CYP-DFU-P1-01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Cynata Therapeutics Limited"
      ],
      "OverallOfficialName": [
            "Jolanta Airey, MD"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Results will be summarised by individual and by treatment group using descriptive statistics."
      ],
      "PrimaryOutcomeMeasure": [
            "Incidence and severity of treatment-emergent adverse events (TEAEs)",
            "Incidence of changes from baseline in haematology, biochemistry, and urinalysis parameters."
      ],
      "PrimaryOutcomeTimeFrame": [
            "24 weeks",
            "24 weeks"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Percentage of area change of study ulcer from baseline to weeks 12 and 24",
            "Number of days to complete ulcer healing",
            "Number of days to 50% ulcer healing",
            "Percentage change in ulcer volume from baseline to weeks 12 and 24",
            "Changes from baseline in ulcer pain assessed using a Numeric Rating Scale",
            "Number clinic/home care visits across groups",
            "Differences across groups on ulcer dressing products used",
            "Changes from baseline in Quality of Life assessed using the Cardiff Wound Impact Schedule",
            "Duration of clinic/home care visits across groups"
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 and 24 weeks",
            "12 and 24 weeks",
            "12 and 24 weeks",
            "12 and 24 weeks",
            "12 and 24 weeks",
            "12 and 24 weeks",
            "12 and 24 weeks",
            "12 and 24 weeks",
            "12 and 24 weeks"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "January 4, 2022"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "March 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "December 21, 2021"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "October 18, 2021"
      ],
      "StudyFirstSubmitQCDate": [
            "December 14, 2021"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}